| name | Bumetanide |
| classification | Loop diuretic |
| pharmacokinetics | | absorption | Rapidly absorbed from the gastrointestinal tract. | | distribution | Distributed throughout the body, including the kidneys. | | metabolism | Metabolized in the liver. | | excretion | Excreted primarily in the urine. |
|
| suggested dosage | | adult | Initial dose: 0.5 to 2 mg orally or intravenously daily, titrated to achieve desired response; max. dose 10 mg daily. May be administered in divided doses. Dose and frequency can be adjusted based on individual patient response and renal function. Consult a healthcare professional for specific dosage recommendations. | | note | Dosage recommendations are general guidelines and must be individualized to the patient's needs. Factors like kidney function, medical history, and other medications are crucial in determining the appropriate dose. |
|
| indications | | 1 | Edema associated with congestive heart failure, cirrhosis, and nephrotic syndrome. | | 2 | Hypertension | | 3 | Acute renal failure (in some cases) |
|
| safety in pregnancy | | category | C | | note | Bumetanide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown adverse effects. Consult with a physician about the risks and benefits specific to your situation. |
|
| safety in breastfeeding | | note | Bumetanide may pass into breast milk. The potential risk to the infant should be carefully weighed against the potential benefit to the mother. Consult a physician for advice. |
|
| side effects | | 1 | Headache | | 2 | Dizziness | | 3 | Lightheadedness | | 4 | Muscle cramps | | 5 | Nausea | | 6 | Vomiting | | 7 | Diarrhea | | 8 | Dehydration | | 9 | Hypotension | | 10 | Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia) | | 11 | Kidney problems (rare) | | 12 | Skin rash |
|
| alternatives | |
| contraindications | | 1 | Severe dehydration | | 2 | Severe electrolyte imbalance | | 3 | Hypersensitivity to bumetanide or other sulfonamides | | 4 | Severe kidney impairment | | 5 | Anuria |
|
| interactions | | 1 | Nonsteroidal anti-inflammatory drugs (NSAIDs) | | 2 | Lithium | | 3 | Digoxin | | 4 | Other diuretics | | 5 | Aminoglycoside antibiotics | | 6 | Other medications that affect electrolyte balance |
|
| warnings and precautions | | 1 | Monitor electrolyte levels regularly, especially potassium. Frequent monitoring may be required for patients with impaired kidney function. | | 2 | May exacerbate existing dehydration. | | 3 | Caution in patients with impaired renal function. | | 4 | Patients with a history of gout may be at increased risk of developing this condition. |
|
| additional information | | mechanism of action | Bumetanide inhibits the sodium-potassium-chloride co-transporter in the loop of Henle, increasing the excretion of sodium, potassium, and chloride in the urine, which leads to increased diuresis and reduced blood volume. | | patient information | Patients should be instructed to monitor their fluid intake and notify their physician if any unusual symptoms arise or their condition worsens. |
|
